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The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy regarding 
cytochrome P450 2D6 (CYP2D6) status and clinical outcomes in tamoxifen therapy. We performed a meta-analysis 
on data from 4,973 tamoxifen-treated patients (12 globally distributed sites). Using strict eligibility requirements 
(postmenopausal women with estrogen receptor–positive breast cancer, receiving 20 mg/day tamoxifen for 5 years, 
criterion 1), CYP2D6 poor metabolizer status was associated with poorer invasive disease–free survival (IDFS: hazard ratio 
= 1.25; 95% confidence interval = 1.06, 1.47; P = 0.009). However, CYP2D6 status was not statistically significant when 
tamoxifen duration, menopausal status, and annual follow-up were not specified (criterion 2, n = 2,443; P = 0.25) or when 
no exclusions were applied (criterion 3, n = 4,935; P = 0.38). Although CYP2D6 is a strong predictor of IDFS using strict 
inclusion criteria, because the results are not robust to inclusion criteria (these were not defined a priori), prospective 
studies are necessary to fully establish the value of CYP2D6 genotyping in tamoxifen therapy.
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Tamoxifen, the pioneering antiestrogenic medicine targeted to 
the tumor estrogen receptor (ER), is used successfully for long-
term adjuvant therapy in breast cancer.1,2 Extensive analyses of 
clinical trials demonstrate a major increase in patient survivor-
ship in ER-positive patients. In this age of personalized medi-
cine, any opportunity to improve response rates with tamoxifen 
should be rigorously investigated. Tamoxifen is considered a 
prodrug, given that hepatic cytochrome P450 2D6 (CYP2D6) 
metabolizes tamoxifen to metabolites (4-hydroxy tamoxifen and 
4-hydroxy-N-desmethyl tamoxifen (endoxifen)) that exhibit sig-
nificantly greater potency in terms of ER-binding affinity3 and 
suppression of estradiol-stimulated cell proliferation.4 CYP2D6-
mediated metabolism is the rate-limiting enzymatic step for the 
formation of endoxifen, the most abundant active metabolite.
There has been great inconsistency among studies that have 
reported the association of known genetic and drug factors 
influencing CYP2D6 enzyme activity with tamoxifen efficacy. 
Therefore, the International Tamoxifen Pharmacogenomics 
Consortium (ITPC) was conceived, and researchers were invited 
to submit their data—both published and unpublished data sets 
regarding CYP2D6 genetic variants and clinical outcomes in 
women treated with tamoxifen in the adjuvant breast cancer 
setting—to allow a meta-analysis of the potential associations 
between CYP2D6 and clinical outcomes.
RESULTS
The ITPC comprises 12 research projects from nine countries 
and three continents that contributed clinical and genetic data 
for a total of 4,973 breast cancer patients treated with tamox-
ifen. In Table 1, we show the sample size by site and criteria. 
Further details for each site are shown in S3c and S5 online. We 
reported preliminary analyses of these collected cohorts before 
complete curation by pooling the data from each site.5 For our 
meta-analyses, three detailed criteria, which ranged from the 
most restrictive (criterion 1) to the most inclusive (criterion 
3), were defined before final curation (see S4 online). In brief, 
criterion 1, derived from the NCCTG 89-30-52 clinical trial, 
consisted of postmenopausal women with surgically resected 
nonmetastatic invasive ER-positive breast cancers who received 
adjuvant tamoxifen monotherapy at a dose of 20 mg/day for an 
intended duration of 5 years, and were followed at least annually 
for recurrence. In addition, analysis of at least CYP2D6*4 was 
required (detailed in S4a online). Criterion 2 included criterion 
1 but allowed both pre- and postmenopausal patients who had 
received any duration of tamoxifen; moreover, annual follow-up 
was not required. Criterion 3 included all samples not excluded 
by any exclusion test for missing data or data inconsistencies 
(least restrictive). Patient characteristics according to each cri-
terion are provided in Table 2.
The meta-analysis results combining the hazard ratio (HR) 
estimates (and the corresponding standard errors (SEs)) from 
each site are shown for all three criteria groups and both clini-
cal outcomes in Table 3. For each of the six clinical outcome/
criteria groups, we give the combined meta-analysis estimate 
across all 12 sites, its SE, and the results of two statistical tests: 
a test of the significance that the meta-HR differs from 1 and a 
test of “homogeneity of the estimates” across sites (a significant 
value for the latter test indicates that there is more variability 
than the derSimonian and Laird random-effects model can rea-
sonably accommodate, suggesting that the meta-estimate and 
its associated P value are suspect). As can be seen for invasive 
disease–free survival (IDFS), the meta-analyses for criteria 2 
and 3 are nearly significantly heterogeneous, whereas there was 
no indication of heterogeneity for criterion 1 (P = 0.899). For 
patients meeting criterion 1, the meta-HR for IDFS was 1.25 
(95% confidence interval = 1.06, 1.47), and for breast cancer–
free interval, it was 1.27 (95% confidence interval = 1.01, 1.61). 
These are both statistically significant, at P = 0.009 and P = 0.04, 
respectively. However, for the criterion 2 (P = 0.25) and criterion 
3 (P = 0.38) subsets, the CYP2D6 HR was not significant for 
either outcome.
In Figure 1, we show the individual HRs for each site for 
subjects meeting criterion 1, assuming an additive genetic 
model for CYP2D6 (coded 0 = extensive metabolizer (EM), 
1 = intermediate metabolizer (IM), and 2 = poor metabolizer 
(PM)) as estimated from a Cox proportional-hazards model 
using additional risk covariates to predict clinical outcome. 
Corresponding figures for criteria 2 and 3 are provided in S6 
online. (Note that the list of covariates used in the Cox models 
included age at primary diagnosis, menopause status at diagno-
sis, metastatic disease at primary diagnosis, maximum tumor 
dimension, number of positive nodes, grade, smoking status, 
ER and progesterone receptor status, intended tamoxifen dose 
and duration, systemic therapy before surgery, chemotherapy, 
radiation treatment, adjuvant aromatase inhibitor therapy, and 
additional hormone therapy. The specific set of covariates used 
for each site was chosen from this list so as to retain at least 70% 
of the patients from that site; hence, the exact set of covariates 
used differs in each site’s Cox model. Moreover, several of these 
covariates were used as inclusion/exclusion items in the basic 
definitions of the three basic criteria subset groups and thus 
became irrelevant for those analyses.)
Table 1  Sample size by site and criteria 
Criterion
Site (N)
1 2 3 4 5 6 7 8 9 10 11 12 Total
1 0 70 124 60 212 243 0 847 5 222 179 34 1,996
2 0 127 208 98 212 304 0 898 10 289 228 69 2,443
3 174 320 282 265 214 391 801 1,140 165 516 397 270 4,935
Total 174 320 282 267 214 423 801 1,140 165 519 398 279 4,973
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Table 2  Baseline patient and tumor characteristics 
Characteristic Criterion 1 (1,996 patients) Criterion 2 (2,443 patients) Criterion 3 (4,935 patients)
Age at diagnosis, years: data reported in binned ages
  Median [65–69] [60–64] [60–64]
  Range 55 (ages 41–95) 75 (ages 21–95) 76 (ages 21–96)
Menopausal status 
—no. (%)
Menopausal status By age Menopausal status By age Menopausal status By age
  Premenopausal (age ≤ 50) 0 (0.0%) 54 (2.7%) 241 (9.9%) 414 (16.9%) 607 (12.3%) 1,207 (24.5%)
  Postmenopausal (>50) 1,688 (84.6%) 1,922 (96.3%) 1,714 (70.2%) 1,997 (81.7%) 3,267 (66.2%) 3,642 (73.8%)
  Not available 308 (15.4%) 20 (1.0%) 488 (20.0%) 32 (1.3%) 1,061 (21.5%) 86 (1.7%)
Tumor size—no. (%): maximum dimension of tumor reported (if multiple tumors, largest one is ≤2 cm)
  ≤2 cm 1,071 (53.7%) 1,327 (54.3%) 2,303 (46.7%)
  >2 cm 752 (37.7%) 882 (36.1%) 2,182 (44.2%)
  Unknown 173 (8.7%) 234 (9.6%) 450 (9.1%)
Nodal status—no. (%): number of positive nodes
  Zero nodes 1,243 (62.3%) 1,531 (62.7%) 2,423 (49.1%)
  1–3 nodes 407 (20.4%) 461 (18.9%) 1,281 (26.0%)
  4–9 nodes 103 (5.2%) 111 (4.5%) 438 (8.9%)
  > 9 nodes 43 (2.2%) 45 (1.8%) 185 (3.7%)
  Not available 200 (10.0%) 295 (12.1%) 608 (12.3%)
Grading—no. (%): 0.5 to 1.49 considered G1, 1.5 to 2.49 G2, etc.
  G1 249 (12.5%) 317 (13%) 456 (9.2%)
  G2 1,148 (57.5%) 1,324 (54.2%) 1,965 (39.8%)
  G3 330 (16.5%) 398 (16.3%) 838 (17.0%)
  Unknown 269 (13.5%) 295 (12.1%) 1,676 (34.0%)
ER status—no. (%)
  ER-positive 1,996 (100.0%) 2,443 (100.0%) 4,675 (94.7%)
  ER-negative 0 (0.0%) 0 (0.0%) 158 (3.2%)
  Unknown 0 (0.0%) 0 (0.0%) 102 (2.1%)
PgR status—no. (%)
  PgR-positive 1,479 (74.1%) 1,847 (75.6%) 3,634 (73.6%)
  PgR-negative 273 (13.7%) 302 (12.4%) 665 (13.5%)
  Unknown 244 (12.2%) 294 (12.0%) 102 (2.1%)
Radiotherapy—no. (%): radiation therapy
  Yes 1,138 (57.0%) 1,412 (57.8%) 2,868 (58.1%)
  No 720 (36.1%) 842 (34.5%) 1,507 (30.5%)
  Unknown 244 (12.2%) 189 (7.7%) 560 (11.3%)
CYP2D6 metabolizer status
  Extensive 893 (44.7%) 1,077 (44.1%) 2,286 (46.3%)
  Intermediate 985 (49.3%) 1,230 (50.3%) 2,311 (46.8%)
  Poor 118 (5.9%) 136 (5.6%) 244 (4.9%)
  Unknown 0 (0.0%) 0 (0.0%) 94 (1.9%)
CYP2D6 metabolizer types
  EM/UM 17 (0.9%) 23 (0.9%) 49 (1.0%)
  IM/UM 2 (0.1%) 2 (0.1%) 4 (0.1%)
  EM/EM 874 (43.8%) 1,052 (43.1%) 2,233 (45.2%)
  PM/UM 7 (0.4%) 7 (0.3%) 12 (0.2%)
Table 2  Continued on next page
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Site-specific product-limit estimates of the three CYP2D6 
metabolizer status genotype groups (EM, IM, and PM) are 
shown in Figures 2 and 3 for criterion 1 patients. Sites 1 and 
7 had no subjects who met inclusion/exclusion for criterion 1. 
The corresponding figures for patients meeting criteria 2 and 3 
are shown in S6 online. As seen in Figure 2, for IDFS sites, 3, 5, 
and 8 show a strong significant effect in the direction expected 
by the known pharmacokinetic effects of CYP2D6 on endoxifen 
exposure, namely, a poorer clinical response for the IM and/or 
PM genotype groups. Other sites show a trend in the expected 
direction between the IM and EM groups, but the much smaller 
PM group is often inconsistent with the expectation, and the 
separation in the three survival curves is not strong enough to 
reach statistical significance (e.g., sites 6 and 12). For some sites, 
there is no hint of any significant difference (e.g., sites 2, 4, 10, 
and 11), and for one of these, site 2, the direction of effect is 
exactly opposite than expected. There is a danger in overinter-
preting such “trends” (either in favor or against expectation) 
when there is no statistically significant difference, because some 
level of site-to-site variation is to be expected. The key ques-
tion is not whether such variation exists but whether it cent-
ers over the null hypothesis or over the alternative; this is the 
question that the meta-analysis is designed to answer. However, 
these simple product-limit survival curves show great study-to-
study heterogeneity, which complicates both the analyses and 
the interpretation. We have similar heterogeneous results for 
the breast cancer–free interval outcome, shown in Figure 3. 
The corresponding figures in S6 online show a similar pattern 
for the subsets of patients meeting criteria 2 and 3, although 
the heterogeneity seems to be even more pronounced as the 
exclusion criteria are loosened. This is not a surprising result, 
considering that the criteria themselves impose a certain level 
of homogeneity.
DISCUSSION
Prospective pharmacology studies consistently demonstrate that 
CYP2D6 genetic variants are associated with variable plasma 
concentrations of endoxifen.4,6 Endoxifen exposure is related 
to duration of tamoxifen use and dose, wherein an increase 
in the tamoxifen dose (from 20 to 40 mg daily) significantly 
increases endoxifen exposure in patients with reduced or null 
CYP2D6 metabolism but not in CYP2D6 EMs.7 However, coad-
ministration of CYP2D6-inhibiting drugs4 reduces CYP2D6 
enzyme activity, and nonadherence to tamoxifen is more com-
monly observed in patients with normal or increased CYP2D6 
metabolism.8
Table 3  Meta-analyses of CYP2D6 HRs on clinical outcome in inclusion/exclusion criteria subsets 
IDFS BCFI
meta-estimates P value meta-estimates P value
Hr 95% CI Homoga Associationb Hr 95% CI Homoga Associationa
Criterion 1 1.25 (1.06,1.47) 0.899 0.009 1.27 (1.01,1.61) 0.858 0.041
Criterion 2 1.17 (0.90,1.52) 0.055 0.249 1.21 (0.889,1.65) 0.130 0.224
Criterion 3 1.07 (0.92,1.26) 0.099 0.382 1.10 (0.868,1.35) 0.114 0.352
BCFI, breast cancer–free interval; Homog, homogeneity; HR, hazard ratio; IDFS, invasive disease–free survival; ITPC, International Tamoxifen Pharmacogenomics Consortium.
aThe homogeneity P value tests the hypothesis that the individual ITPC site estimates meet the statistical random-effects modeling assumptions of the meta-analysis. 
A significant value indicates that there is significant heterogeneity among the sites, which casts doubt on the “combinability” of the studies for that parameter and on the 
validity of the corresponding association test. bThe association P value tests the hypothesis that the combined meta-analysis estimate of the HR is significantly different from the 
null hypothesis value of HR = 1.
Characteristic Criterion 1 (1,996 patients) Criterion 2 (2,443 patients) Criterion 3 (4,935 patients)
  EM/IM 327 (16.4%) 407 (16.7%) 693 (14.0%)
  EM/PM 496 (24.8%) 616 (25.2%) 1,230 (25.1%)
  IM/IM 64 (3.2%) 94 (3.8%) 174 (3.5%)
  IM/PM 91 (4.6%) 106 (4.3%) 192 (3.9%)
  PM/PM 118 (5.9%) 136 (5.6%) 244 (4.9%)
  Unknown 0 (0.0%) 0 (0.0%) 94 (1.9%)
DNA source
  Blood 996 (49.9%) 1,344 (55.0%) 2,513 (50.9%)
  Tumor—Frozen 431 (21.6%) 500 (20.5%) 1,575 (31.9%)
  Tumor—FFPE 569 (28.5%) 598 (24.5%) 659 (13.4%)
  Normal—FFPE 0 (0.0%) 0 (0.0%) 174 (3.5%)
  Unknown 0 (0.0%) 1 (0.0%) 14 (0.3%)
CYP2D6, cytochrome P450 2D6; EM, extensive metabolizer; ER, estrogen receptor; FFPE, formalin-fixed–paraffin-embedded; IM, intermediate metabolizer; PgR, progesterone 
receptor; PM, poor metabolizer; UM, unknown metabolizer.
Table 2  Continued
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Despite the consistent pharmacogenetic effects of CYP2D6 on 
endoxifen exposure, there is considerable controversy regarding 
the validity of CYP2D6 as a predictor of tamoxifen outcome.9,10 
Although recent secondary analyses from the Arimidex, 
Tamoxifen, Alone or in Combination (ATAC) trial and the Breast 
International Group (BIG) 1-98 study11,12 did not demonstrate 
an association between CYP2D6 and tamoxifen outcome, these 
studies provoked criticism due to concerns regarding genotyp-
ing error and the analysis of small subsets of the main trials.13–16
By contrast, a secondary analysis from another large pro-
spective adjuvant tamoxifen trial, the Austrian Breast and 
Colorectal Cancer Study Group 8 (ABCSG 8), demonstrated 
that for women treated with 5 years of adjuvant tamoxifen at a 
dose of 20 mg/day, CYP2D6 PMs had a statistically significant 
higher odds of recurrence or death as compared with CYP2D6 
EMs, and CYP2D6 PMs/IMs and PMs/EMs tended to exhibit 
a higher odds of recurrence as compared with patients without 
the PM alleles. However, this effect was not observed for patients 
who had switched to anastrozole, a drug not metabolized by 
CYP2D6. These data suggest that the effects of CYP2D6 geno-
type may be masked if patients receive a shorter duration of 
tamoxifen or other active drugs besides tamoxifen, which alter 
the hazard for recurrence.17 
We approached the tamoxifen controversy by performing a 
global meta-analysis of available clinical and CYP2D6 genetic 
data of tamoxifen-treated breast cancer patients. All groups from 
across the world with both published and unpublished CYP2D6 
data were invited to participate. We initially presented a pooled 
analysis of these data,5 in which we found no association between 
CYP2D6 and IDFS. Following this presentation, we developed a 
new analysis plan (not defined before the initial negative pres-
entation), which included the following: (i) articulation of three 
criteria to analyze the data according to the quality of the genetic 
and clinical data, (ii) additional curation to obtain missing clini-
cal and genetic data, and (iii) a new statistical analysis plan, which 
applied a random-effects meta-analysis strategy instead of a pooled 
analysis strategy. Notably, Criterion 1 is most stringent, requir-
ing strict control for as many pharmacologic factors as possible 
known to affect endoxifen exposure, which include use of tamox-
ifen monotherapy, genotyping of multiple CYP2D6 alleles for accu-
rate CYP2D6 phenotype assignment, use of one tamoxifen dose 
(20 mg), and intended duration of tamoxifen use for 5 years. In 
addition, eligibility for this cohort was restricted to women with 
invasive ER-positive status, postmenopausal breast cancer, and 
the requirement for annual follow-up, parameters required in any 
prospective clinical trial and that were requirements of criterion 
1 (patients who were knowingly not followed were excluded from 
criterion 1), but not from criteria 2 and 3. These factors may have 
contributed to the substantial increase in heterogeneity comparing 
criterion 1 with criteria 2 and 3. However, it should be noted that 
these criteria impose a certain bias because the majority of negative 
studies submitted to the ITPC were observed in criteria 2 and 3.
In general, a substantial number of subjects comprising cri-
terion 3 had misclassification of the predicted drug metabo-
lism phenotype due to the lack of a comprehensive coverage 
of loss-of-function alleles.18,19 More than 20 loss-of-function 
alleles out of 100 known CYP2D6 genetic variants contributed 
to a frequency of ~8% of PMs in a population of European 
descent. Limiting the analysis to the most common such allele, 
CYP2D6*4, as was frequently done in the older published lit-
erature, will result in misclassification of 35% of PMs, thereby 
falsely assigning the undetected PMs to the EM or IM groups. 
Notably, 871/1,996 patients comprising criterion 1 had optimal 
CYP2D6 phenotype assessment obtained by AmpliChip geno-
typing, and this may have contributed to the robustness of cri-
terion 1 results, which demonstrated an association between 
CYP2D6 and tamoxifen treatment outcome (breast cancer–free 
interval: HR = 1.27, 95% confidence interval = 1.01–1.61).
The ITPC intended to perform a global study including sev-
eral thousand patient samples; however, the majority of the 
subjects were not comprehensively genotyped because DNA 
was not of sufficient quality. We performed a subgroup analysis 
using patient samples for which full coverage of alleles by the 
Figure 1   Individual site estimates of hazard ratios of CYP2D6 genotype on 
clinical outcome, along with the meta-analyses for the criterion 1 subset. 
(a) Invasive disease–free survival (IDFS) outcome. (b) Breast cancer–free 
interval (BCFI) outcome.
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AmpliChip genotyping platform was available using criterion 
1 (871/1,635 AmpliChip-genotyped subjects met criterion 1). 
When confined to the Amplichip subjects, the estimates of the 
pharmacodynamic HRs for CYP2D6 were similar to what they 
were for the entire set of subjects meeting criterion 1.
A major source of potential genotyping errors may be 
related to DNA source. CYP2D6 is one of the most difficult 
genes to genotype because of the numerous polymorphisms 
and adjacent pseudogenes. Some platforms cannot detect the 
presence of the *5 deletion, particularly in DNA derived from 
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Figure 2   Site-specific effects of CYP2D6 metabolizer status on clinical outcomes for subjects meeting inclusion criterion 1 (outcome = invasive disease–free 
survival (IDFS)).
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formalin-fixed–paraffin-embedded (FFPE) tissue. However, 
several sites used multiple platforms to validate their geno-
typing data, reducing potential genotyping errors across the 
entire data set. Importantly, CYP2D6 genotypes obtained from 
blood-derived DNA reflect the patients’ germ-line genotypes, 
known to influence endoxifen plasma concentrations. By con-
trast, CYP2D6 genotypes from tumor-derived DNA may be 
subject to error due to somatic mutation by loss of heterozy-
gosity, known to affect the CYP2D6 locus at 22q13 in up to 
30% of breast tumors.20–22 Thus, when CYP2D6 genotype is 
derived from tumor samples, an excess number of homozy-
gotes may result as a consequence of loss of heterozygosity. 
This form of genotyping error is revealed by Hardy–Weinberg 
Equilibrium (HWE) testing, as was observed in the Breast 
Figure 2   Continued
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International Group 1-98 study, in which strong departures 
from HWE (to a magnitude of 10–92) were observed, leading 
to a call for retraction of this article.3,12,16
For criterion 1, 49.9% of our patient DNA samples originated 
from blood, 21.6% from fresh-frozen tissues, and 28.5% from 
FFPE tissues. For criterion 2, 55.0% samples originated from blood, 
20.5% were fresh-frozen tissues, and 24.5% from FFPE tissues. For 
criterion 3, 50.9% of DNA samples originated from blood, 31.9% 
from fresh-frozen tumor, 13.4% from FFPE tumor tissues, and 
3.5% from FFPE normal tissue. Although we cannot exclude the 
presence of somatic events leading to misclassification of CYP2D6 
genotype, as evident from HWE deviation identified in data from 
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Figure 3   Site-specific effects of CYP2D6 metabolizer status on clinical outcomes for subjects meeting inclusion criterion 1 (outcome = breast cancer–free 
interval (BCFI)).
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some sites, comprehensive testing for HWE did not reveal signifi-
cant violations across most sites. Moreover, the extent of deviation 
from HWE in the *4 allele was not associated with sites that evinced 
less clinical benefit from tamoxifen in patients who were assessed 
to be PMs in terms of their CYP2D6 status. This suggests that geno-
typing errors are unlikely to be a major issue in our analyses.
Our findings are subject to the shortcomings commonly 
encountered when performing retrospective “biomarker” 
studies. In our study, most sites were unable to collect or 
control for the factors known to alter endoxifen exposure, 
including dose and duration of tamoxifen administration 
and patients’ adherence to the regimen. Although tamoxifen 
adherence is increasingly recognized as a critical factor for 
drug efficacy,23 most studies evaluating tamoxifen biomarkers 
have not controlled for adherence. Other confounders include 
limited CYP2D6 allele coverage and lack of information 
Figure 3   Continued
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regarding the coadministration of CYP2D6 inhibitors, leading 
to potential misclassification of the CYP2D6 drug metabolism 
phenotype. Therefore, our meta-analysis results depend heav-
ily on which subgroup of patients we include. If we accept that 
utmost precautions must be applied to avoid the distortion 
of results from influences derived from the aforementioned 
shortcomings, it follows that merely increasing the numbers of 
subjects without controlling the quality of input data, as done 
in our preliminary overview analysis,5 may result in hetero-
geneity that masks the effect of a pharmacokinetic biomarker 
such as CYP2D6. From this, we conclude that until results 
from prospective adjuvant studies are available, women who 
meet criterion 1 as established in this and other independ-
ent cohorts (ABCSG 8) should be counseled regarding the 
potential impact of CYP2D6 on the effectiveness of adjuvant 
tamoxifen, and potent CYP2D6 inhibitors should be avoided 
in these patients. Prospective adjuvant studies are needed to 
determine whether genotype-guided selection of hormonal 
therapy will improve the outcomes of women with early-stage 
ER-positive breast cancer, and results from ongoing prospec-
tive studies in the metastatic setting are eagerly awaited. 
A similarly motivated study on warfarin is currently being 
conducted in the Clarification of Optimal Anticoagulation 
through Genetics trial.24
By strict clinical and genotype criteria, reduced CYP2D6 
metabolism is associated with a higher risk of recurrence (as 
measured by IDFS) in tamoxifen-treated women. However, 
the heterogeneity observed across sites contributing data to 
the ITPC points to the likely influence of critical confounding 
factors unlikely to be controllable in global retrospective stud-
ies. This study demonstrates the complexity of performing a 
retrospective biomarker study that focuses on the genetic fac-
tors that affect exposure to an active metabolite, endoxifen, for 
a drug, tamoxifen, administered for 5 years. Our observation 
that <50% of the patients in this study met the basic eligibility 
criteria—in terms of similar disease, treatment, and control for 
critical pharmacological factors such as dose and duration of 
tamoxifen—provides insight into possible reasons for the dis-
crepancies in the literature on CYP2D6 and tamoxifen. Although 
CYP2D6 is a predictor of IDFS in a subset of patients treated 
with tamoxifen, the lack of an effect in the entire heterogeneous 
study population suggests that prospective studies are neces-
sary to finally establish whether genotype-guided selection of 
hormonal therapy improves clinical outcomes of women with 
ER-positive breast cancer.
METHODS
Data collection and study cohorts. The ITPC invited any research 
group from across the world that had published or unpublished 
CYP2D6 data to participate in this meta-analysis. The ITPC com-
prises 12 research projects for a total of 4,973 breast cancer patients 
treated with tamoxifen. This retrospective study does not include a 
control group not treated with tamoxifen. These data were curated at 
the PharmGKB (Pharmacogenomics Knowledge Base, http://www.
pharmgkb.org). Consent for participation in the ITPC and DNA col-
lection, CYP2D6 genetic testing, and submission of data was obtained 
under local ethical review board permissions.
We collected information on clinical factors previously shown to 
be associated with breast cancer therapy and prognosis that were 
available from the information received from the sites. These data 
included demographic characteristics, cancer history, cancer recur-
rence, use of other therapies, use of concomitant medications known 
to affect CYP2D6 phenotype, ER status, and classic prognostic factors 
such as tumor size and number of affected lymph nodes. Information 
was also collected regarding the presence of CYP2D6 genetic vari-
ants (*2, *3, *4, *5, *6, *10, *17, and *41, categorized by their DNA 
sources), for which coverage of these alleles varied by site. For 1,635 
subjects, CYP2D6 variants assessable from blood DNA using the 
AmpliChip CYP450 test (Roche) were collected. A complete list of 
the information collected is detailed in S1–S3 online, including the 
project-specific CYP2D6 genotype assays used and the DNA source. 
Independent confirmation of CYP2D6 genotypes was not performed 
owing to lack of access to subjects’ samples. The clinical outcome 
variable was either breast cancer–free interval or IDFS, as previously 
defined.25 The complete data set of genotypes and clinical variables 
is available at http://www.pharmgkb.org.
Statistical analysis. Because the ITPC was not a prospectively 
defined multicenter study with a common protocol, there is poten-
tial for considerable study-to-study heterogeneity. Therefore, we 
did not analyze the combined data as a single series even though 
we had access to individual-level data from all studies. Rather, we 
applied a random-effects meta-analysis strategy. This provided 
estimates of the effect of CYP2D6 in each study’s data separately, 
allowing us to examine the consistency of the results across sites. 
The meta-analysis is a two-stage procedure. In the first stage, we 
fit proportional-hazards models to the data from each of the ITPC 
sites separately, predicting clinical outcome after surgery from 
CYP2D6 genotype and other relevant covariates. These analyses 
produced a set of 12 parameter estimates of the HRs of CYP2D6 
genotypes on outcome, along with their corresponding SEs (one 
for each site). In the second stage, we used a random-effects meta-
analysis procedure26 to test for study heterogeneity (i.e., whether 
the 12 studies met the assumptions of the meta-analysis sufficiently 
so as to be combinable using that method). When the heterogeneity 
was not significant, we combined the log-HRs into a single, meta-
analysis estimate of the effect of CYP2D6 on tamoxifen-treated 
recurrence and/or survival outcomes. The DerSimonian and Laird 
method also provides a penalty in its test of overall association for 
moderate levels of study-to-study heterogeneity (i.e., for hetero-
geneity that is not so severe as to be statistically significant). This 
method is therefore conservative in its conclusions when heteroge-
neity is a potential issue.
SUPPLEMENTARY MATERIAL is linked to the online version of the paper at 
http://www.nature.com/cpt
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
 3 There has been extensive controversy with regard to 
the association between CYP2D6 genetic variants and 
the clinical outcomes of tamoxifen use.
WHAT QUESTION DID THIS STUDY ADDRESS?
 3 The ITPC was established to address this contro-
versy and to determine the association of CYP2D6 
status with IDFS in tamoxifen-treated early-stage, 
ER-positive breast cancer.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 3 We found that CYP2D6 genotype was associated with a 
higher risk of recurrence in patients meeting the strict 
criterion. However, the observation of substantial 
heterogeneity in cohorts 2 and 3 suggests that study 
design factors that cannot be controlled retrospec-
tively may obscure the predictive utility of CYP2D6 
genotype. This study demonstrates the complexity of 
performing a retrospective biomarker study.
HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY 
AND THERAPEUTICS
 3 Although CYP2D6 is a predictor of IDFS in a subset of 
patients treated with tamoxifen monotherapy, the lack 
of an effect in the entire heterogeneous study popula-
tion suggests that prospective studies are necessary 
to fully establish the value of CYP2D6 genotyping in 
tamoxifen therapy.
This work is licensed under a Creative 
Commons Attribution-nonCommercial-no 
Derivative Works 3.0 license. To view a copy of this license, 
visit http://creativecommons.org/licenses/by-nc-nd/3.0/
ClInICAl PHArmACologY & THerAPeUTICS | VOLUME 95 NUMBER 2 | FEBRUARY 2014 227
